Changes in Hong Kong stocks | Jietai Technology-P (07666) rose more than 6% across tracks, giants lay out AI4S Pharmaceuticals commercialization results, nanoForge welcomed the centralized release period

The Zhitong Finance App learned that Jitai Technology-P (07666) rose by more than 6%. As of press release, it had risen 5.01% to HK$17.62, with a turnover of HK$72,429,900.

According to news, recently, according to market media reports, Anthropic has built a wet laboratory in the San Francisco Bay Area of the United States to extend biological research from computer simulation to real experiments, and explore using Claude to command robots to carry out experiments. Dongwu Securities pointed out that global tech giants are deeply embedded in biomedicine through different paths, and AI pharmaceuticals have entered the strategic entry stage. Dry and wet closed loop is the core operating logic of AIDD, and wet experiments are irreplaceable. BOC Securities believes that experimental verification is an important part of the AI pharmaceutical industry chain to achieve long-term value, and the expansion of verification demand is expected to drive the simultaneous expansion of demand for upstream scientific research services such as gene synthesis and protein reagents.

It is worth mentioning that in the first half of the year, the commercialization results of Jietai Technology's NanoForge entered a centralized release period. The revenue during the period exceeded 154 million yuan, exceeding 47% of last year's annual revenue. Since the launch of NanoForge, the world's first AI nano-delivery platform, the new “dry test+wet experiment+smart body” R&D paradigm has fully covered the complete chain of AI protein generation, in vivo delivery technology and next-generation immunotherapy development, forming a closed loop of continuous learning and nano-delivery data barriers. It continues to break through extrachepatic delivery, providing underlying support for the exploration of accurate AI delivery and cellular programming.